Tocilizumab

ActemraActemra SC

安挺樂靜脈點滴注射劑安挺樂皮下注射劑

200mg/10ml/vial162mg/0.9ml/syringe

05. BIOLOGIC AND IMMUNOLOGIC AGENTS; ;

05.05. IMMUNOLOGIC AGENTS;;

Interleukin-6 Receptor Antagonist

類風濕性關節炎(RA)、巨細胞動脈炎(GCA)
重度新型冠狀病毒(SARS-CoV-2)感染症

C 動物試驗顯示有致畸胎的結果，但沒有針對孕婦或動物有對照組的研究可證明其危險性。

Unknown

Rheumatoid arthritis
<100 kg: SC 162 mg once every other week; increase to 162 mg once every week based on clinical response
≥100 kg: 162 mg once every week
IVF 4 mg/kg once every 4 weeks; may be increased to 8 mg/kg once every 4 weeks based on clinical response (maximum dose: 800 mg)
Giant cell arteritis
SC 162 mg once every week (in combination with a tapering course of glucocorticoids); based on clinical considerations, may consider 162 mg once every other week (with a tapering course of glucocorticoids).
COVID-19, hospitalized patients:
IVF(rate≧60minutes)
Children ≥2 years, adolescents and adult: 8 mg/kg (patients ≥30 kg) or 12 mg/kg (patients <30 kg) as a single dose(maximum dose: 800 mg) in combination with glucocorticoids
Tocilizumab is not recommended when baricitinib is substituted for glucocorticoids
Cytokine release syndrome:
8 mg/kg (patients ≥30 kg) or 12 mg/kg (patients <30 kg) once (maximum dose: 800 mg [based on chimeric antigen receptor T-cell CRS dosing]); if clinical improvement does not occur within 8 to 24 hours after, up to 3 additional doses may be administered (with at least an 8-hour interval between consecutive doses)
Polyarticular juvenile idiopathic arthritis (PJIA)
Children ≥2 years and Adolescents: 8 mg/kg/dose(patients ≥30 kg) or 10 mg/kg/dose(patients <30 kg) every 4 weeks; maximum dose: 800 mg/dose.
Systemic juvenile idiopathic arthritis (SJIA)
8 mg/kg (patients≥30 kg) or 12 mg/kg (patients <30 kg) every 2 weeks; maximum dose: 800 mg/dose.

Increased ALT and AST, increased serum cholesterol, injection site reaction, neutropenia

1.ANC<2000/mm3 or PLT<100×103/mm3 or ALT或AST>1.5倍正常值，不建議使用

1.需冷藏於2-8℃
2.給藥期間不可施打活性疫苗
3.皮下注射劑型：
(1)每次注射應輪換不同注射部位
(2)使用之前，應先將預充針筒或預充針筒附注射筆自冰箱中取出，去除外盒後，在室溫下靜置30分鐘
4.靜脈注射劑型：
(1)稀釋：
a.BW<30kg: 先由50ml之0.45%或0.9%NaCl中抽出與Actemra施打劑量同體積之輸注液丟棄，再將Actemra加入混合均勻。
b.BW≧30kg: 先由100ml之0.45%或0.9%NaCl中抽出與Actemra施打劑量同體積之輸注液丟棄，再將Actemra加入混合均勻。
c.藥品以0.9%NaCl稀釋後於2-8℃或室溫下，避光可保存24小時。
d.藥品以0.45%NaCl稀釋後於2-8℃或室溫下，避光可保存4小時。
(2)輸注時間需大於60分鐘，不可靜脈推注(push 或bolus)
(3)不可與其他藥物共用輸注管線
(4)治療期間若發生嚴重感染(除Covid-19外)，請暫停治療，直到感染情況獲得控制

建立者

103617

建立時間

2014-01-20 13:02:34

維護者

103617

維護時間

2024-01-10 11:29:32